CompletedPhase 2/3

Topical Cetirizine in Androgenetic Alopecia in Females

Egypt66 participantsStarted 2020-07-25

Plain-language summary

Cetirizine is a safe and selective, second-generation histamine H1 receptor antagonist, widely used in daily practice. A study showed that cetirizine causes a significant reduction in both the inflammatory cell infiltrate and PGD2 production. A pilot study on topical cetirizine showed that cetirizine increased total hair density, terminal hair density and diameter. Also, its lower potential side effects if compared with other drugs commonly used for AGA, as minoxidil, can promote a wider use and better compliance of cetirizine in the future for the treatment of AGA. Combinations of therapies are likely to be more efficacious than single treatments. Treatments to clinically improve scalp hair density and reduce mid-pattern thinning leading to improved scalp coverage are highly important for the affected women. On the basis of the above evidence and lacking studies that confirm the effectiveness of cetirizine in AGA treatment, the aim of this study is to evaluate the efficacy and tolerability of topical cetirizine in female patients with AGA.

Who can participate

Age range

20 Years – 50 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Females with androgenetic alopecia of age 20-50 years.
. Patients experiencing active hair loss within the last 12 months.
. Sinclair scale 2, 3 and 4.
. Patients willing to continue their current regimen of vitamins and nutritional supplements and not start any new vitamins or nutritional supplements for the duration of the study.
. Patients willing to use a mild non-medicated shampoo and conditioner for the duration of the study.
. Patients who did not receive topical or systemic treatment for androgenetic alopecia or prostaglandins in the last 6 months.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The change from baseline in number of terminal hairs and vellus hair

Timeframe: baseline, 12, 24 weeks

The change from baseline in hair shaft thickness

Timeframe: baseline, 12, 24 weeks

The change from baseline in terminal and vellus hair density

Timeframe: baseline, 12, 24 weeks

The change in patient self-assessment from baseline

Timeframe: baseline, 6, 12, 18, 24 weeks

Trial details

NCT IDNCT04481412

SponsorCairo University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-11-30

View on ClinicalTrials.gov More Androgenetic Alopecia trials

Plain-language summary

Who can participate

Age range

20 Years – 50 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Females with androgenetic alopecia of age 20-50 years.
. Patients experiencing active hair loss within the last 12 months.
. Sinclair scale 2, 3 and 4.
. Patients willing to continue their current regimen of vitamins and nutritional supplements and not start any new vitamins or nutritional supplements for the duration of the study.
. Patients willing to use a mild non-medicated shampoo and conditioner for the duration of the study.
. Patients who did not receive topical or systemic treatment for androgenetic alopecia or prostaglandins in the last 6 months.

What they're measuring

The change from baseline in number of terminal hairs and vellus hair

Timeframe: baseline, 12, 24 weeks

The change from baseline in hair shaft thickness

Timeframe: baseline, 12, 24 weeks

The change from baseline in terminal and vellus hair density

Timeframe: baseline, 12, 24 weeks

The change in patient self-assessment from baseline

Timeframe: baseline, 6, 12, 18, 24 weeks